Patents by Inventor Gregor Jordan
Gregor Jordan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240117029Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.Type: ApplicationFiled: November 14, 2023Publication date: April 11, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
-
Publication number: 20240102999Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.Type: ApplicationFiled: November 29, 2023Publication date: March 28, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Uwe DAHL, Gregor JORDAN, Roland STAACK
-
Publication number: 20240083993Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.Type: ApplicationFiled: June 15, 2023Publication date: March 14, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
-
Patent number: 11913945Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced by applying an inert reference antibody that does not penetrate into said tissue, whereby the inert reference antibody is administered 2 to 10 minutes prior to obtaining the tissue and blood sample.Type: GrantFiled: December 29, 2020Date of Patent: February 27, 2024Assignee: Hoffmann-La Roche Inc.Inventors: Martin Schaefer, Sylvia Rottach, Gregor Jordan, Kay-Gunnar Stubenrauch, Roland Staack, Kevin Brady
-
Patent number: 11892448Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.Type: GrantFiled: July 10, 2019Date of Patent: February 6, 2024Assignee: HOFFMANN-LA ROCHE INC.Inventors: Uwe Dahl, Gregor Jordan, Roland Staack
-
Publication number: 20230393125Abstract: Herein is reported a method for determining free antigen of an antibody in an undiluted serum sample comprising the steps of a) applying the undiluted sample to a solid phase on which a capture antibody has been immobilized to form a capture antibody-antigen complex, wherein the capture antibody competes with the antibody for binding to a first epitope on the antigen, b) applying to the solid phase a tracer antibody to form a capture antibody-antigen-tracer antibody complex, wherein the tracer antibody specifically binds to a second epitope on the antigen, wherein the epitope of the tracer antibody is not overlapping with the epitope of the capture antibody on the antigen, and c) determining the free antigen of the antibody by determining the tracer antibody in the capture antibody-antigen-tracer antibody complex.Type: ApplicationFiled: December 16, 2022Publication date: December 7, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Gregor JORDAN, Martin SCHAEFER, Maria VIERT
-
Patent number: 11739142Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.Type: GrantFiled: December 16, 2020Date of Patent: August 29, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Jens Fischer, Guy Georges, Anton Jochner, Gregor Jordan, Hubert Kettenberger, Joerg Moelleken, Tilman Schlothauer, Georg Tiefenthaler, Valeria Runza, Meher Majety, Martin Schaefer, Maria Viert, Shu Feng, Wei Shiong Adrian Ho, Siok Wan Gan, Runyi Adeline Lam, Michael Gertz
-
Publication number: 20230063268Abstract: Herein is reported a method for the determination of the presence of anti-drug antibodies in a sample comprising the steps of incubating the sample with MgCl2 at a final concentration in the range of 1 N to 12 N; adding a tracer antibody and incubating the sample thereafter; incubating the isolated tracer antibody-anti-drug antibody-complexes with a detection antibody conjugated to a detectable label and determining the presence of anti-drug antibodies if a signal above a threshold level is obtained.Type: ApplicationFiled: November 7, 2022Publication date: March 2, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Gregor JORDAN, Roland STAACK
-
Publication number: 20220357340Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , tissue = C t ? m ? A ? b , tissue , det . C t ? i ? s ? sue , sample - C r ? e ? f ? m ? A ? b , tissue , det . C t ? i ? s ? sue , sample C r ? e ? f ? m ? A ? b , plasma . det . * C t ? m ? A ? b , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.Type: ApplicationFiled: June 14, 2022Publication date: November 10, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Kevin BRADY, Gregor JORDAN, Sylvia ROTTACH, Martin SCHAEFER, Roland STAACK, Kay-Gunnar STUBENRAUCH
-
Publication number: 20220275070Abstract: The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxysmal nocturnal hemoglobinuria (PNH). The dosage and treatment regimen of the present invention include the administration of an anti-C5 antibody, preferably of the anti-C5 antibody Crovalimab, with loading doses followed by the administration of (a) maintenance dose(s) of the anti-C5 antibody to the subject, wherein the initial administered loading dose is intravenously given to the subject and the remaining loading and maintenance doses are subcutaneously administered in a lower dosage as the intravenously administered loading dose.Type: ApplicationFiled: July 30, 2020Publication date: September 1, 2022Applicant: HOFFMANN-LA ROCHE INC.Inventors: Alexandre Antoine Bernard Sostelly, Simon Bertrand Marie Buatois, Antoine Soubret, Félix Grégoire Jason Jaminion, Gregor Jordan, Christoph Bucher, Jean-Eric Charoin
-
Publication number: 20220275071Abstract: The present invention relates to a dosage and administration regimen of anti-C5 antibodies, particularly of the anti-C5 antibody Crovalimab, for use in a method of treating or preventing C5-related disease in a subject, including paroxysmal nocturnal hemoglobinuria (PNH). The dosage and treatment regimen of the present invention include the administration of an anti-C5 antibody, preferably of the anti-C5 antibody Crovalimab, with loading doses followed by the administration of (a) maintenance dose(s) of the anti-C5 antibody to the subject, wherein the initial administered loading dose is intravenously given to the subject and the remaining loading and maintenance doses are subcutaneously administered in a lower dosage as the intravenously administered loading dose.Type: ApplicationFiled: July 30, 2020Publication date: September 1, 2022Applicant: HOFFMANN-LA ROCHE INC.Inventors: Alexandre Antoine Bernard Sostelly, Simon Bertrand Marie Buatois, Antoine Soubret, Félix Grégoire Jason Jaminion, Gregor Jordan, Christoph Bucher, Jean-Eric Charoin
-
Publication number: 20220074928Abstract: Herein is reported a method for the determination of a bispecific antibody in a serum-containing sample comprising the steps of first incubating a solid phase to which a capture antibody specifically binding to the bispecific antibody has been immobilized with the sample to form an immobilized capture antibody-bispecific antibody-complex, thereafter incubating the solid phase with a replacement antibody that competes with the capture antibody for binding to the bispecific antibody and thereby forming a solution comprising a replacement antibody-bispecific antibody-complex, and determining in the solution the replacement antibody-bispecific antibody-complex.Type: ApplicationFiled: November 12, 2021Publication date: March 10, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Gregor JORDAN, Achim LUTZ, Maria VIERT
-
Publication number: 20210364504Abstract: Herein is reported a method for determining the concentration of a therapeutic antibody in a tissue of an experimental animal to whom the therapeutic antibody had been administered, wherein the interference from residual blood in a tissue sample of the experimental animal, which is used for determining the concentration of the therapeutic antibody in said tissue, is reduced, wherein the concentration of the therapeutic antibody in the tissue of the experimental animal is calculated with the following formula: C tmAb , tissue = C tmAb , tissue , det . C tissue , sample - C refmAb , tissue , det . C tissue , sample C refmAb , plasma . det . * C tmAb , plasma , det . wherein CtmAb,tissue,det.=obtained by determining the concentration of the therapeutic antibody in the tissue sample of the experimental animal, CtmAb,plasma,det.Type: ApplicationFiled: December 29, 2020Publication date: November 25, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Martin Schaefer, Sylvia Rottach, Gregor Jordan, Kay-Gunnar Stubenrauch, Roland Staack, Kevin Brady
-
Publication number: 20210188960Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.Type: ApplicationFiled: December 16, 2020Publication date: June 24, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Jens FISCHER, Guy GEORGES, Anton JOCHNER, Gregor JORDAN, Hubert KETTENBERGER, Joerg MOELLEKEN, Tilman SCHLOTHAUER, Georg TIEFENTHALER, Valeria RUNZA, Meher MAJETY, Martin SCHAEFER, Maria VIERT, Shu FENG, Wei Shiong Adrian HO, Siok Wan GAN, Runyi Adeline LAM, Michael GERTZ
-
Publication number: 20200300852Abstract: Herein is reported an immunoassay for quantifying the amount of anti-drug antibody, which anti-drug antibody can specifically bind to a drug antibody, which drug antibody can specifically bind to a therapeutic target, in a serum or plasma sample comprising the steps of a) incubating the serum or plasma sample at a pH value that is about the pI value of the target, and optionally removing formed precipitate after the incubation, b) incubating the serum or plasma sample obtained in step a) at a pH value of about 2, and optionally centrifuging the incubated sample to remove formed precipitate, c) adjusting the pH value to about 7.Type: ApplicationFiled: November 27, 2018Publication date: September 24, 2020Inventors: Uwe Dahl, Gregor Jordan, Roland Staack, Miriam Moheysen-Zadeh
-
Publication number: 20200173989Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.Type: ApplicationFiled: July 10, 2019Publication date: June 4, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Uwe Dahl, Gregor Jordan, Roland Staack
-
Patent number: 10458981Abstract: Herein is reported a method for determining in a sample the (total, i.e. binding competent) amount of a ligand of a ligand-binding protein (therapeutic) comprising the following steps in the following order: subjecting the sample to an acid treatment, forming in solution a non-covalent complex comprising i) an anti-ligand antibody, ii) the ligand, and iii) labelled ligand-binding protein, by adding anti-ligand antibody and labelled ligand-binding protein to the sample, and determining the amount of the complex and thereby determining the amount of the ligand of the ligand-binding protein.Type: GrantFiled: June 15, 2018Date of Patent: October 29, 2019Assignee: Hoffmann-La Roche Inc.Inventors: Gregor Jordan, Roland Staack
-
Publication number: 20190011440Abstract: Herein is reported a method for determining in a sample the (total, i.e. binding competent) amount of a ligand of a ligand-binding protein (therapeutic) comprising the following steps in the following order: subjecting the sample to an acid treatment, forming in solution a non-covalent complex comprising i) an anti-ligand antibody, ii) the ligand, and iii) labelled ligand-binding protein, by adding anti-ligand antibody and labelled ligand-binding protein to the sample, and determining the amount of the complex and thereby determining the amount of the ligand of the ligand-binding protein.Type: ApplicationFiled: June 15, 2018Publication date: January 10, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Gregor JORDAN, Roland STAACK
-
Patent number: 9797900Abstract: Thus, herein is reported a method for analyzing/characterizing circulating immune complexes (CICs) formed in vivo comprising a size-exclusion chromatography of a sample obtained from a mammal to which the drug had been administered at least once for determining the weight/size of the immune complexes, optionally a second non-SEC chromatography, and at least one immunoassay, whereby the immune complex is characterized by the correlation of the immune complex size and the immunoassay result/read-out. Also reported herein is the use of a method as reported herein for determining a correlation to altered pharmacokinetics, for determining loss or reduction of efficacy, for determining neutralization of natural counterparts of the drug, for determining immune and hypersensitivity reactions, including serum sickness/type III hypersensitivity reaction/immune complex-mediated disease.Type: GrantFiled: September 5, 2014Date of Patent: October 24, 2017Assignee: F. HOFFMAN-LA ROCHE AGInventors: Uwe Dahl, Gregor Jordan, Roland Staack
-
Publication number: 20150168396Abstract: Herein is reported a method for the determination of the binding affinity of a binder and its ligand comprising the step of determining based on the result of an immunoassay the fraction of free binder in a sample comprising binder, ligand and binder-ligand-complexes for at least two different binder:ligand ratios in the sample, and if the determined fraction of free binder is not comparable for all used binder:ligand ratios then the binder:ligand ratio in the sample is lowered and the sample is re-analyzed by the same immunoassay, and calculating based on the fraction of free binder in the previous step the binding affinity for the binder to its ligand.Type: ApplicationFiled: August 2, 2013Publication date: June 18, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Uwe Dahl, Gregor Jordan, Roland Staack